From Idea to Market: Product Lifecycle Management in the Pharmaceutical Industry

From Idea to Market: Product Lifecycle Management in the Pharmaceutical Industry (Market Focus)

Published Date: July 2007

Published By: Datamonitor

Page Count: 11

Order Code: R313-23917

Questions About This Report

E-mail a Colleague

Printable Page

Fax Your Order

Description

Table of Contents

Search Inside
this Report

Similar
Products

DATAMONITOR VIEW
CATALYST
SUMMARY
ANALYSIS: Product lifecycle management will transform the drug development lifecycle process; The nature of a drug's lifecycle necessitates a PLM strategy; PLM addresses key business challenges facing the pharmaceutical industry; A greater focus on decreasing time to market is driving adoption of PLM; Harmonizing product portfolios from M&A activities sets the stage for PLM; Reducing the challenges and cost associated with regulatory compliance; The nature of the pharmaceutical drug pipeline is changing; Complexity of pharmaceutical products is increasing; The end of the Blockbuster era signifies more candidates in the pipeline; Successful PLM for the pharmaceutical industry prevails over several constraining factors; Repurposing software from other industries makes the pharmaceutical industry suspicious; The traditional autonomous-business-unit mentality inhibits adoption of PLM; PLM does not mean an antidote to new product development
ACTIONS: Articulate strategic business benefits of your PLM investment decisions; Take a holistic approach to PLM; Understand how PLM changes the lifecycle processes of a pharmaceutical product
APPENDIX
APPENDIX: Definitions; Abbreviations; References; Methodology; Further reading; Ask the analyst; Datamonitor consulting; Disclaimer
List of Tables: Table 1: Global PLM spending in the pharmaceutical industry by sector 2006-2012
List of Figures: Figure 1: The pharmaceutical product lifecycle is highly regulated, more complex and longer than other industries; Figure 2: Drug discovery licensing dependence of the top 10 pharmaceutical companies; Figure 3: Drug discovery licensing dependence of the top 10 pharmaceutical companies